01.06.2020 ijBio Index
Infojet ClubijBio: Farm Involved ijBio-Index:
June,1 2020:
AstraZeneca (AZN) $55,2 (+1%)
Inovio (INO) $14,9 (+0.7%)
Moderna (MRNA) $62,2 (+1%)
Abbot (ABT) $93 (-2%)
Gilead (GILD). $75,3 (-3.5%)
Adaptive (ADPT) $39 (+1%)
CytoDyn (CYDY) $3 (0%)
AbbVie (ABBV) $90,7 (-2%)
Deciphera (DCPH) $60 (+3.6%)
Sorrento (SRNE) $5 (-1%)
At close 01.06.20= 498 (-0,62%)
previous day <---> next day
At close 29.05.20= 501,4 (+3,8%)
At close 28.05.20=483 (+0,83)
At close 27.05.20= 479 (-1,1%)
Index was launched 26.05.20 = 504
--
Gilead's Remdesivir Shows Mixed Results In Coronavirus Test; Shares Dive
US STOCKS-Wall Street closes higher as recovery signs soothe protest, pandemic worries
Stock Market Today With Jim Cramer: Civil Unrest on Main Street
Coronavirus update: NJ eyes next reopen phase; protests, curfews fan fears of COVID spread
The Stock Market Is Rising Despite All the Negative Headlines. Here’s Why.
2 “Strong Buy” Healthcare Stocks That Offer Massive Potential Gains
A new batch of data for Gilead Sciences’ remdesivir points to efficacy but it’s no ‘silver bullet’
Abbott Downgraded to Sell by Goldman Sachs
US STOCKS-U.S. stocks gain as signs of recovery offset protests, economic worries
INSIGHT-Scientists hunt pandemic hotspots in race to test vaccines
US STOCKS-Wall St gains as recovery hopes overshadow U.S. protests
It was a relatively easy decision: J&J Exec shares experience working in the frontlines
Best Dividend Stocks for June 2020
US STOCKS-Wall St flat as recovery hopes offset U.S. protests, China tensions
Gilead's stock falls on remdesivir, Eli Lilly begins human study of possible COVID-19 treatment
Gilead Falls On Mixed Results From Late-Stage Remdesivir Study In Moderate COVID-19
Gilead Stock Is Dropping Because the Latest Data on Its Coronavirus Drug Just Wasn’t Good Enough
Gold Little Changed Near $1,750 as U.S. Protests Square off with Reopenings
3 Biotech Quick Picks to Invest $5,000 This Week
US STOCKS-Wall St rises as recovery hopes offset U.S. protests, China tensions
Gilead Reports Positive Late-Stage Study Results for Remdesivir in Patients With Moderate COVID-19
Moderna Doses First Participants In Phase 2 Study Of Coronavirus Vaccine
Market Awaits Major Economic Data This Week
Gilead Falls as Drug Has Only Small Benefit in Large Trial
Gilead Reports Positive Trial Results for Covid Drug Remdesivir
Is the Options Market Predicting a Spike in Agenus (AGEN) Stock?
Moderna’s Covid-19 Vaccine Enters Next Phase of Testing. Goldman Sachs Is Upbeat.
Moderna Starts a Phase 2 Clinical Trial for Its COVID-19 Vaccine
Gilead's remdesivir shows modest improvement in moderate COVID-19 patients
Gilead's stock falls on remdesivir data in moderately ill patients
Gilead says remdesivir helped moderate COVID-19 patients improve
5 Top Stocks Up 100%+ in May With More Room to Run
Dow Jones Futures: Tesla Leads 5 Stocks Looking To Break Out Decisively In Coronavirus Market Rally
Gilead trades that made millions on COVID-19 drug news raise eyebrows
Why virus stocks are driving market volatility
Biotech ETFs Are Soaring. These Four Are Still Worth Considering.
Facebook staff plan 'virtual walkout' over response to Trump posts
Small-business owner says she stayed open by accepting 'new normal' amid coronavirus
Coronavirus update: NJ eyes next reopen phase; protests, curfews fan fears of COVID spread
Half of Americans dipped into their retirement savings to get through the pandemic: study
Yahoo Finance